Share this article
Share this article
ResearchAndMarkets.com s offering.
Biosimilar Lymphocyte Modulator Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar lymphocyte modulator market.
Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis and Celltrion.
The global lymphocyte modulator market is expected to decline from $1.29 billion in 2019 to $1.21 billion in 2020 at a compound annual growth rate (CAGR) of -5.57%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.67 billion in 2023
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at
(2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations.
(3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
Reports Fourth Quarter Revenues of $11.1 Billion; Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46; Full-Year Loss Per Share of $3.99 and Non-GAAP EPS of $6.44 Completes Acquisition of MyoKardia, Expanding Leading Cardiovascular Franchise Announces Debt Tender Offer for an Aggregate Purchase Price of Up to $4.0 Billion Delivers Positive Results from … Reports Fourth Quarter Revenues of $11.1 Billion; Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46; Full-Year Loss Per Share of $3.99 and Non-GAAP EPS of $6.44 Completes Acquisition of MyoKardia, Expanding Leading Cardiovascular Franchise
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients have a better CAR T response than others and what can be done to improve the treatment s effectiveness. In a new study published in
Home / Top News / Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial
Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021
Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy
WORCESTER, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on MB-107 and MB-207, its lentiviral gene therapies for the treatment of X-linked severe combined immunodeficien